NASDAQ:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free AEZS Stock Alerts $2.09 +0.14 (+7.18%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$1.95▼$2.1550-Day Range$1.73▼$2.1952-Week Range$1.36▼$3.30Volume81,023 shsAverage Volume16,382 shsMarket Capitalization$10.16 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Aeterna Zentaris alerts: Email Address Aeterna Zentaris MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside617.7% Upside$15.00 Price TargetShort InterestHealthy0.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.32 out of 5 starsMedical Sector454th out of 928 stocksPharmaceutical Preparations Industry191st out of 415 stocks 3.5 Analyst's Opinion Consensus RatingAeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAeterna Zentaris has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.35% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aeterna Zentaris has recently decreased by 22.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 1.9 News and Social Media Coverage News SentimentAeterna Zentaris has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.73% of the stock of Aeterna Zentaris is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MillPub😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.Click here to save your seat and join the next LIVE workshop! About Aeterna Zentaris Stock (NASDAQ:AEZS)Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.Read More AEZS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesMay 1, 2024 | globenewswire.comAeterna Zentaris Announces Effective Date of Share ConsolidationApril 30, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)May 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.April 29, 2024 | americanbankingnews.comAeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Down 22.1% in AprilApril 28, 2024 | finance.yahoo.com12 ChatGPT Penny Stock Picks Right NowApril 28, 2024 | americanbankingnews.comContrasting BioMarin Pharmaceutical (NASDAQ:BMRN) and Aeterna Zentaris (NASDAQ:AEZS)April 22, 2024 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.comApril 2, 2024 | theglobeandmail.comAuxly Cannabis Group: Top 10 Undervalued Healthcare Sector Stocks on TSX (XLY)May 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.March 28, 2024 | globenewswire.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 27, 2024 | benzinga.comAEterna Zentaris: Q4 Earnings InsightsMarch 27, 2024 | globenewswire.comAeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyMarch 13, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsMarch 12, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsFebruary 28, 2024 | thestreet.comAeterna Zentaris Inc.February 26, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 15, 2024 | globenewswire.comAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproNovember 14, 2023 | morningstar.comAEterna Zentaris Inc AEZSNovember 9, 2023 | msn.comAeterna Zentaris GAAP EPS of -$0.85November 9, 2023 | finance.yahoo.comAeterna Zentaris Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | theglobeandmail.comAEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)October 30, 2023 | theglobeandmail.comAEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)October 11, 2023 | finance.yahoo.comAeterna Zentaris to Participate at the Virtual Investor Ask the CEO ConferenceSeptember 12, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Monday (AEZS)September 5, 2023 | finance.yahoo.comAeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)August 10, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)See More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/02/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+617.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,550,000.00 Net Margins-368.01% Pretax Margin-367.99% Return on Equity-63.20% Return on Assets-37.35% Debt Debt-to-Equity RatioN/A Current Ratio8.01 Quick Ratio8.00 Sales & Book Value Annual Sales$4.50 million Price / Sales2.26 Cash FlowN/A Price / Cash FlowN/A Book Value$3.75 per share Price / Book0.56Miscellaneous Outstanding Shares4,860,000Free Float4,851,000Market Cap$10.16 million OptionableNo Data Beta1.57 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.President, CEO & Executive DirectorMr. Giuliano La FrattaSenior VP of Finance & CFODr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical DevelopmentDr. Matthias GerlachSenior Vice President Manufacturing & Supply ChainKey CompetitorsGalera TherapeuticsNASDAQ:GRTXGuardion Health SciencesNASDAQ:GHSIMolecular TemplatesNASDAQ:MTEMEterna TherapeuticsNASDAQ:ERNAAlterity TherapeuticsNASDAQ:ATHEView All Competitors AEZS Stock Analysis - Frequently Asked Questions Should I buy or sell Aeterna Zentaris stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks. What is Aeterna Zentaris' stock price target for 2024? 1 equities research analysts have issued 1 year price targets for Aeterna Zentaris' shares. Their AEZS share price targets range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 617.7% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts. How have AEZS shares performed in 2024? Aeterna Zentaris' stock was trading at $1.86 on January 1st, 2024. Since then, AEZS stock has increased by 12.4% and is now trading at $2.09. View the best growth stocks for 2024 here. Are investors shorting Aeterna Zentaris? Aeterna Zentaris saw a drop in short interest in April. As of April 15th, there was short interest totaling 16,900 shares, a drop of 22.1% from the March 31st total of 21,700 shares. Based on an average daily volume of 15,900 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company's stock are sold short. View Aeterna Zentaris' Short Interest. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our AEZS earnings forecast. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its earnings results on Wednesday, March, 27th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by $0.19. The biopharmaceutical company earned $0.12 million during the quarter. Aeterna Zentaris had a negative trailing twelve-month return on equity of 63.20% and a negative net margin of 368.01%. When did Aeterna Zentaris' stock split? Shares of Aeterna Zentaris reverse split before market open on Friday, May 3rd 2024. The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG). Who are Aeterna Zentaris' major shareholders? Aeterna Zentaris' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEZS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
